Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double-blind placebo controlled trial

Chris Fox; Monica Crugel; Ian Maidment; Bjorn Henrik Auestad; Simon Coulton; Adrian Treloar; Clive Ballard; Malaz Boustani; Cornelius Katona; Gill Livingston

doi:10.1371/journal.pone.0035185

Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double-blind placebo controlled trial

Chris Fox, Monica Crugel, Ian Maidment, Bjorn Henrik Auestad, Simon Coulton, Adrian Treloar, Clive Ballard, Malaz Boustani, Cornelius Katona, Gill Livingston

Research output: Contribution to journal › Article › peer-review

117 Citations (Scopus)

Abstract

Agitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary hypothesis, memantine is superior to placebo for clinically significant agitation, in patients with moderate-to-severe AD.

Original language	English
Article number	e35185
Journal	PLoS One
Volume	7
Issue number	5
DOIs	https://doi.org/10.1371/journal.pone.0035185
Publication status	Published - 2 May 2012

Keywords

Aged
Aged, 80 and over
Alzheimer Disease
Dementia
Female
Humans
Male
Memantine
Psychomotor Agitation

Access to Document

10.1371/journal.pone.0035185Licence: CC BY

Cite this

@article{a3ce214160374feeaad5ca508aad0be7,

title = "Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double-blind placebo controlled trial",

abstract = "Agitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary hypothesis, memantine is superior to placebo for clinically significant agitation, in patients with moderate-to-severe AD.",

keywords = "Aged, Aged, 80 and over, Alzheimer Disease, Dementia, Female, Humans, Male, Memantine, Psychomotor Agitation",

author = "Chris Fox and Monica Crugel and Ian Maidment and Auestad, {Bjorn Henrik} and Simon Coulton and Adrian Treloar and Clive Ballard and Malaz Boustani and Cornelius Katona and Gill Livingston",

year = "2012",

month = may,

day = "2",

doi = "10.1371/journal.pone.0035185",

language = "English",

volume = "7",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "5",

}

TY - JOUR

T1 - Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double-blind placebo controlled trial

AU - Fox, Chris

AU - Crugel, Monica

AU - Maidment, Ian

AU - Auestad, Bjorn Henrik

AU - Coulton, Simon

AU - Treloar, Adrian

AU - Ballard, Clive

AU - Boustani, Malaz

AU - Katona, Cornelius

AU - Livingston, Gill

PY - 2012/5/2

Y1 - 2012/5/2

N2 - Agitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary hypothesis, memantine is superior to placebo for clinically significant agitation, in patients with moderate-to-severe AD.

AB - Agitation in Alzheimer's disease (AD) is common and associated with poor patient life-quality and carer distress. The best evidence-based pharmacological treatments are antipsychotics which have limited benefits with increased morbidity and mortality. There are no memantine trials in clinically significant agitation but post-hoc analyses in other populations found reduced agitation. We tested the primary hypothesis, memantine is superior to placebo for clinically significant agitation, in patients with moderate-to-severe AD.

KW - Aged

KW - Aged, 80 and over

KW - Alzheimer Disease

KW - Dementia

KW - Female

KW - Humans

KW - Male

KW - Memantine

KW - Psychomotor Agitation

U2 - 10.1371/journal.pone.0035185

DO - 10.1371/journal.pone.0035185

M3 - Article

C2 - 22567095

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e35185

ER -